Home Cart Sign in  
Chemical Structure| 945614-12-0 Chemical Structure| 945614-12-0

Structure of Pexmetinib
CAS No.: 945614-12-0

Chemical Structure| 945614-12-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Pexmetinib is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line.

Synonyms: ARRY-614

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Pexmetinib

CAS No. :945614-12-0
Formula : C31H33FN6O3
M.W : 556.63
SMILES Code : O=C(NCC1=CC(F)=CC=C1OC2=CC3=C(N(CCO)N=C3)C=C2)NC4=CC(C(C)(C)C)=NN4C5=CC=C(C)C=C5
Synonyms :
ARRY-614
MDL No. :MFCD28502055
InChI Key :LNMRSSIMGCDUTP-UHFFFAOYSA-N
Pubchem ID :24765037

Safety of Pexmetinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Pexmetinib

RTK
MAPK
TLR

Isoform Comparison

Biological Activity

Target
  • Tie-2

  • p38 MAPK

In Vitro:

Cell Line
Concentration Treated Time Description References
Ba/F3T315I cells 10 µM Screening for selective inhibition of ABL1T315I, pexmetinib showed specific cytotoxicity PMC11286508
Healthy CD34+ cells 0.1μM 14 days Assess the reversal effect of pexmetinib on TNF-α-induced myelosuppression PMC5398415
MDA-MB-231 cells 0–60 μM 48 and 96 hours Pexmetinib inhibited migration and invasion of MDA-MB-231 cells. PMC9253705
Bone marrow macrophage cells (BMMs) 0, 0.1, 0.2, 0.4 μM 5 days Pexmetinib inhibited RANKL-induced osteoclast formation and bone resorption. PMC9253705

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD-1 mice and nu/nu NCr mice HEK-Tie2 xenograft model Oral varying doses Single dose Assess the in vivo inhibitory effect of pexmetinib on p-p38 and pTie2 PMC5398415
BALB/c mice EMT6 and CT26 syngeneic models Oral 30mg/kg Once daily for 21 days Evaluate the antitumor efficacy of pexmetinib in combination with immune checkpoint inhibitors PMC10462255
BALB/c nu/nu mice Breast cancer bone metastasis induced osteolysis model Intraperitoneal injection 10 mg/kg Every three days for one month Pexmetinib suppressed breast cancer cell-induced osteolytic lesions. PMC9253705
Immunodeficient mice KCL22-DasR xenograft model Intraperitoneal injection 40 mg/kg Daily treatment Pexmetinib significantly inhibited tumor growth PMC11286508

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.80mL

0.36mL

0.18mL

8.98mL

1.80mL

0.90mL

17.97mL

3.59mL

1.80mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories